Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Company Overview

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Key Stats

• Today's Range: $5.41 to $6.05
• 50-Day Range: $2.94 to $11.13
• 52-Week Range: $1.62 to $29.28
• Volume: 350,874 shs
• Average Volume: 2.01 million shs
• Market Capitalization: $10.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Dogwood Therapeutics Stock Analysis - MarketRank™

Dogwood Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dogwood Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dogwood Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dogwood Therapeutics are expected to grow in the coming year, from ($6.43) to ($4.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dogwood Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dogwood Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dogwood Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DWTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dogwood Therapeutics does not currently pay a dividend.

Dividend Growth

Dogwood Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DWTX.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.78

News Sentiment

Dogwood Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Dogwood Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 9 people have searched for DWTX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

5 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of Dogwood Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.05% of the stock of Dogwood Therapeutics is held by institutions.

DWTX Stock Analysis - Frequently Asked Questions

How have DWTX shares performed this year?

Dogwood Therapeutics' stock was trading at $2.49 at the beginning of 2025. Since then, DWTX shares have increased by 122.1% and is now trading at $5.53.
View the best growth stocks for 2025 here.

How were Dogwood Therapeutics' earnings last quarter?

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) posted its quarterly earnings data on Monday, March, 31st. The company reported ($6.29) earnings per share for the quarter, missing the consensus estimate of ($1.49) by $4.80.

When did Dogwood Therapeutics' stock split?

Dogwood Therapeutics shares reverse split on Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Dogwood Therapeutics' major shareholders?

Top institutional investors of Dogwood Therapeutics include FNY Investment Advisers LLC (0.65%).

How do I buy shares of Dogwood Therapeutics?

Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/31/2025
• Today: 4/25/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DWTX
• CIK: 1818844
• Web: www.dwtx.com
• Phone: (866) 620-8655
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +73.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -217.12%
• Return on Assets: -172.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.94 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: 1,911,000
• Free Float: 1,169,000
• Market Cap: $11.05 million
• Optionable: N/A
• Beta: 1.99